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Abstract
The cancer stem cell hypothesis proposes that tumors  arise in
stem or progenitor cells generating in tumors driven by a
subcomponent that retains cancer stem cell properties. Recent
evidence supports the hypothesis that the BRCA1 gene involved in
hereditary breast cancer plays a role in breast stem cell function.
Furthermore, studies using mouse BRCA1 knockout models
provide evidence for the existence of heterogeneous cancer stem
cell populations in tumors generated in these mice. Although these
populations may arise from different stem/progenitor cells, they
share the expression of a common set of stem cell regulatory
genes and show similar characteristics in in vitro mammosphere
assays and xenograft models. Furthermore, these ‘cancer stem
cells’ display resistance to chemotherapeutic agents. These
studies suggest that breast tumors may display intertumor stem
cell heterogeneity. Despite this heterogeneity, cancer stem cells
may share common characteristics that can be used for their
identification and for therapeutic targeting.
In a recent publication, Wright and colleagues [1] used a
mouse knockout model of BRCA1 to demonstrate cellular
heterogeneity of cancer stem cells. They generated 16 cell
lines from five independent BRCA1Δexon 11/p53+/– mouse
mammary tumors. They then examined the expression of cell-
surface markers associated with cancer stem cells in these
cell lines. Interestingly, cells derived from one tumor
contained populations that were characterized as CD44+/
CD24– and that displayed stem cell properties, whereas cells
derived from another tumor contained a cancer stem cell
population that was characterized by CD133 expression. The
CD44+/CD24– phenotype previously has been described as
identifying a cell population with stem cell properties in
human breast tumors [2].
Sheridan and colleagues [3] recently reported that a number
of basal mammary carcinoma cell lines contain a
CD44+/CD24– cell population, whereas luminal cell lines do
not. In contrast to human cancer cells, normal mouse
mammary stem cells have been reported to have a CD24+
phenotype [4]. Although CD133 previously has not been
reported to be expressed on breast cancer stem cells, this
marker is expressed on a variety of other human cancer stem
cells, including those of the brain, prostate, and pancreas.
Interestingly, Wright and colleagues [1] found no overlap
between the CD44+/CD24– and the CD133+ cell popula-
tions. This suggests that there may be heterogeneity within
stem cell populations in BRCA1 tumors. As has previously
been proposed for sporadic breast tumors, this heterogeneity
may potentially result from different cells of origin [5].
The cancer stem cell hypothesis proposes that tumors arise
in either normal stem or progenitor cells through the
disregulation of self-renewal processes. This results in tumors
that are driven by a cellular subcomponent that retains stem
cell properties. Recently, our group reported that BRCA1
functions as a regulator of breast stem cell fate [6]. This
suggests the possibility that the heterogeneity of stem cells
reported by Wright and colleagues represents different cells
of origin in tumors that contain CD44+/CD24– stem cells and
those that contain CD133+ stem cells. Despite the fact that
there was no overlap in expression of CD44+/CD24– and
CD133+ cell populations in these cell lines, both cancer stem
cell populations overexpressed the stem cell genes Oct4,
Notch1, ALDH1, Fgfr1, and Sox1. This is consistent with our
recent report that ALDH1 is a marker of both normal and
malignant human mammary stem cells [7]. Furthermore, this
suggests that a common set of ‘stemness’ genes may be
shared between heterogeneous populations of cancer stem
cells.
Wright and colleagues used both in vitro assays as well as
xenograft models to demonstrate the stem cell properties of
the CD44+/CD24– and CD133+ cell populations. Both of
these populations form mammospheres in vitro, a
characteristic shared by normal [8] and malignant [9]
mammary stem cells. Interestingly, cells cultured as mammo-
spheres or those with stem cell markers show resistance to
chemotherapeutic agents such as cisplatin compared with
the bulk of the cell population. The resistance of breast
cancer stem cells to both radiation [10] and chemotherapy
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[11] has also been reported by other investigators. In
addition, the proportion of cells characterized as CD44+/
CD24low significantly increases following neoadjuvant chemo-
therapy in patients with breast cancer [11], demonstrating
the clinical relevance of these concepts. Although trans-
porters such as BCRP are overexpressed in some stem cells
[12], Wright and colleagues [1] did not find an increase in
expression of ABC transporters in either stem cell population.
Thus, the mechanisms of drug resistance in these cells
remains to be elucidated. Other potential mechanisms of
chemoresistance of cancer stem cells include overexpression
of chemotherapy metabolizing enzymes such as aldehyde
dehydrogenase 1, changes in cell cycle kinetics, and over-
expression of anti-apoptotic proteins [13].
A number of therapeutic approaches are being developed to
therapeutically target breast cancer stem cells. Wright and
colleagues demonstrate that the HSP90 inhibitor 17-DMAG
sensitizes these cells to chemotherapy. These in vitro
experiments have potential clinical implications since HSP90
inhibitors are currently in clinical trials. Furthermore, these
studies indicate the feasibility of using in vitro mammosphere
assays for the screening of compounds that are able to target
cancer stem cells.
In summary, recent studies suggest that both hereditary and
sporadic breast tumors may originate through the dis-
regulation of self-renewal pathways in normal mammary stem
and/or progenitor cells. The resulting tumors may be driven
by heterogeneous populations of cancer stem cells. This
heterogeneity may reflect different cells of origin and/or
different mutation profiles in these cells. These hetero-
geneous cancer stem cell populations, in turn, may determine
the overall molecular phenotype of tumors as assessed by
molecular profiling. The development of suitable in vitro and
mouse models should accelerate research aimed at identify-
ing these diverse cancer stem cell populations. This should
facilitate the identification of suitable targets for the develop-
ment of strategies aimed at cancer prevention and therapy.
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